Revvity supplies EONIS-Q kits for NHS newborn SCID and SMA screening
- NHS England
- London
- Call-off from a framework agreement
- 1 April 2026 to 31 March 2029
NHS England ordered EONIS-Q assay kits from Revvity for newborn screening evaluations in four laboratories.
The kits serve the NHS Newborn Blood Spot in-service evaluation for Severe Combined Immuno-Deficiency (SCID), which was already running. The order also covers a second evaluation, for Spinal Muscular Atrophy (SMA). Revvity supplies the reagents and materials the screening laboratories need for both.
The £4,074,117 call-off from a framework was awarded in March 2026 and runs for three years, to March 2029.
Contract ends March 2029
- What
- Laboratory consumables, reagents and chemicals
- Buyer
- NHS England
- Supplier
- Revvity
- Value
- £4.07m
- How it was bought
- Call-off from a framework agreement
- Dates and next
- Apr 2026 to Mar 2029